
Biosignal Vector
69 posts

Biosignal Vector
@BiosignalVector
Biotech | clinical data | asymmetric catalysts. Tracking emerging therapeutics across multiple indications.
Katılım Kasım 2025
32 Takip Edilen2 Takipçiler

@ChrisCamillo Wow! Good to know. I guess you are a ninja with short dates calls, but we already knew that. I’ll probably do a hybrid approach bc I’m not a ninja. We all have our risk tolerance and skills, as you always remind us.
English

@ChrisCamillo AMZN could possibly make an insane move. Question though: you’ve mentioned that your AMZN thesis could take 1-2 years to play out. Any clues as to how you approach that with options? Are you partly going back to the longer 6-9 month contracts you talk about in your book?
English

@ChrisCamillo Looking forward to the next show as always, Chris! Your insights are so helpful.
English
Biosignal Vector retweetledi

Fantastic News from Larry Williams. Williams a NerveGen patient: his nerve pain has gone away!! #lightbox" target="_blank" rel="nofollow noopener">reddit.com/r/NervGen_Nerv… $NGENF Has a NVG-291 drug that allows spinal cord nerves to regenerate. He is an example of someone that has regained the ability to walk just after 6 weeks of treatment. The benefits keep coming, as once the nerves start to grow again, they keep going, even after the drug stops. Here is the most recent video interview of CEO youtube.com/watch?v=U_RI5n… This drug should have been approved 6 months ago, superb safety profile and in FDA drug tests it has cured paralysis cases. If RFK knew, maybe he could push this thru.

YouTube
English
Biosignal Vector retweetledi

Biosignal Vector retweetledi

Capricor just reported its first quarter 2026 financial results and provided a recent corporate update. Click here to read the full release: bit.ly/4udKQcy
$CAPR #DMD #Deramiocel

English

@ChrisCamillo Any hints what your strategy was going into these earnings? Just curious how you structure a trade around earnings.
English
Biosignal Vector retweetledi

Bloom Energy Reports Record First Quarter 2026 Results:
• Q1 revenue of $751.1 million,m
• Non-GAAP gross margin of 31.5%
• Raised full year 2026 revenue growth guidance midpoint to ~80% year-over-year
Access the full release here: lnkd.in/gRqrSxXe


English

@ChrisCamillo @Johnhollf And hopefully talk about Amazon earnings? Trying to figure out what I’m comfortable with
English
Biosignal Vector retweetledi

Medicenna CEO, Dr. Fahar Merchant, summarizes the rationale behind #MDNA113, our first-in-class, tumour-targeted, conditionally activated, anti-PD-1-IL-2 bifunctional superkine, currently featured at the American Association for Cancer Research (@AACR ) Annual Meeting.
By prioritizing safety and potency in parallel, we aim to overcome the historic limitations of systemic IL-2 therapies.
Read the full release: ir.medicenna.com/news-releases/…
$MDNAF $MDNA.TO #AACR26 #Immunotherapy #Biotech

English

@ChrisCamillo On today’s show it would be amazing to hear about how you structure trades around earnings. Complicated with IV crush and all that. I’m looking ahead to Amazon earnings and trying to decide what I want to do.
English
Biosignal Vector retweetledi

Unlocking immunologically "cold" tumors is one of oncology's greatest challenges.
We are thrilled to announce that Medicenna will present highly anticipated preclinical data for our first-in-class IL-2-PD-1 Superkine, #MDNA113, at #AACR26 in San Diego!
Read the full PR here: ir.medicenna.com/news-releases/…
$MDNAF $MDNA.TO #Biotech #Oncology #Immunotherapy #CancerResearch
(Disclaimer: MDNA113 is investigational. Post contains forward-looking statements. See SEDAR/SEC filings for risks).
English
Biosignal Vector retweetledi

CAPR PDUFA 8/22
Elijah’s birthday 8/22
What an incredible story this has been. Born for this!
Capricor Therapeutics@Capricor
Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026. Click here to read the announcement: bit.ly/4bz2qk2 #DMD #Deramiocel $CAPR
English
Biosignal Vector retweetledi

The #NeuroOncology space is heating up! Servier’s ~$2.5B acquisition of Day One Biopharma is a major milestone. While entirely independent of Medicenna, it sends a powerful strategic signal about renewed, structural investment in CNS tumors. $MDNAF #Biotech

English

@ChrisCote24 @markland_55 @VPrasadMDMPH I certainly hope so. I wonder who will make necessary decisions in his place though. I guess the next in command?
English

@markland_55 @VPrasadMDMPH Personally I think he has 0.0 influence or authority at this point. It’s too much of a liability if he tried to go rouge with approvals, CRLs etc. I believe his access is now gone, badge and laptop turned in.
English

Defining moment for @VPrasadMDMPH who will use the next 6 weeks or less to define his short term legacy at the #FDA
Let’s measure him for what he tries to do with his remaining time
$capr $qure $srpt $xbi
English
Biosignal Vector retweetledi

Nicole Verdun lost her job at the FDA standing up to @VPrasadMDMPH for DMD patients and was proven right when @Capricor released positive phase 3 results in December
Bring her back to lead CBER @DrMakaryFDA she’s a true warrior for rare disease patients
Adam Feuerstein ✡️@adamfeuerstein
EXCLUSIVE: STAT takes you inside the FDA to explain the ouster of Nicole Verdun, the agency's chief regulator of cell and gene therapies. Centered around disagreements over Capricor $CAPR Duchenne therapy and Verdun's management style statnews.com/2025/06/20/fda…
English
Biosignal Vector retweetledi

February 28 is Rare Disease Day 💜
Today, we stand with the more than 300 million people worldwide living with a rare disease — including those affected by Duchenne muscular dystrophy (DMD). At Capricor, our mission is clear: advance innovative therapies and work with urgency to bring new options to patients and families who need them most.
Today and every day, we remain focused on transforming innovation into hope.
#RareDiseaseDay #DMD #RareButNotAlone $CAPR

English





